InsiderTrades

Form 4 for BSX Boston Scientific

Accepted 2024-05-30 00:00:00 ET · period of report 2024-05-29 · accession 0001225208-24-006445 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-05-30 2024-05-29 BSX Mirviss Jeffrey B. EVP, Pres, Periph Intervent S - Sale+OE $75.10 -63.8K 28.0K -69% -$4.79M
D 2024-05-30 2024-05-29 BSX Mirviss Jeffrey B. EVP, Pres, Periph Intervent M - OptEx $17.26 +33.7K 91.8K +58% +$582.1K
D 2024-05-30 2024-05-29 BSX Mirviss Jeffrey B. EVP, Pres, Periph Intervent M - OptEx $0.00 -33.7K 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-05-29 S D 63,802 $75.10 28,022 D — — (F2) Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $74.78 to $75.33, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
2 Common Common Stock 2024-05-29 M A 33,726 $17.26 91,824 D — —
3 Derivative Stock Option (Right to Buy) 2024-05-29 M D 33,726 $0.00 0 D $17.26 · — to 2026-02-22 33,726 Common Stock (F3) Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.